大腸癌是全球第三大被診斷為男女性別的癌症,男性發病率僅次於肺癌和乳腺癌,是僅次於肺癌、肝癌和胃癌的第四大癌症死亡原因。使用5-fluorouracil(5-FU)、irinotecan和oxaliplatin三種組合,合併bevacizumab當作第一線治療BRAF突變的轉移性(metastatic colorectal cancer, mCRC)病人而預後不好時,美國食品藥品監督管理局(FDA)核准第二代BRAF抑制劑Braftovi®(encorafenib)合併使用Erbitux®(cetuximab)於治療具有BRAF V600E突變的轉移性結直腸癌(mCRC)的成人病人。最常見的副作用為疲勞、貧血、肌酸磷酸激酶升高、AST升高和尿路感染。藥物動力學方面:Braftovi®的最高血漿濃度的時間(Tmax)為2小時且至少86%的劑量被吸收,半衰期(t1/2)為3.5小時。
Colorectal cancer is the third most common cancer in the world. The incidence rate of men is second only to lung cancer and breast cancer, and is the fourth leading cause of cancer death after lung cancer, liver cancer and gastric cancer. When using the three combinations of 5-fluorouracil (5-FU), irinotecan and oxaliplatin, combined with bevacizumab as the first-line treatment of BRAF mutation metastatic colorectal cancer (mCRC) patients, the prognosis is not good. The U.S. Food and Drug Administration ( FDA) approved the second-generation BRAF inhibitor Braftovi®(encorafenib) combined with Erbitux®(cetuximab) for the treatment of adult patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation. The most common side effects are fatigue, anemia, increased creatine phosphokinase, increased AST, and urinary tract infections. Pharmacokinetics: The time (Tmax) of the highest plasma concentration of Braftov® is 2 hours and at least 86% of the dose is absorbed and the half-life (t1/2) is 3.5 hours.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。